spacer
home > white papers > Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections - IBT Bioservices
WHITE PAPERS
logo_IBT_Bioser0.jpg

IBT Bioservices

phone +1 877-411-2041
email services@ibtbioservices.com
web http://ibtbioservices.com/
email 21 Firstfield Road, Suite 100, Gaithersburg, MD 20878 USA

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

Introduction

Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.


spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Scitara announces partnership with Agilent to benefit customers with enhanced digital lab connectivity

Marlborough, MA, September 20th, 2022 – Market leading innovator in laboratory digital transformation, Scitara, has announced a partnership with Agilent, a leader in analytical and diagnostic technologies. The announcement enables the integration of Scitara’s Scientific Integration Platform SIP with Agilent’s Software and Informatics Division portfolio of products, including chromatography software and lab workflow management solutions.
More info >>


White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement